Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib
- PMID: 16926628
- DOI: 10.1097/01.cad.0000217433.48870.37
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib
Abstract
Aberrant activation of the epidermal growth factor receptor is frequently observed in neoplasia, notably in tumors of epithelial origin. Attempts to treat such tumors with epidermal growth factor receptor antagonists resulted in remarkable success in recent studies. Little is known, however, about the efficacy of this therapy in biliary tract cancer. Protein expression of epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor-2 was assessed in seven human biliary tract cancer cell lines by immunoblotting. In addition, histological sections from 19 patients with extrahepatic cholangiocarcinoma were analyzed for epidermal growth factor receptor, ErbB-2 and vascular endothelial growth factor receptor-2 expression by immunohistochemistry. Moreover, we sequenced the cDNA products representing the entire epidermal growth factor receptor coding region of the seven cell lines, and searched for genomic epidermal growth factor receptor amplifications and polysomy by fluorescence in-situ hybridization. Cell growth inhibition by gefitinib erlotinib and NVP-AEE788 was studied in vitro by automated cell counting. In addition, the anti-tumoral effect of erlotinib and NVP-AEE788 was studied in a chimeric mouse model. The anti-tumoral drug mechanism in this model was assessed by MIB-1 antibody staining, terminal deoxynucleotidyl transfer-mediated dUTP nick end-labelling assay, von Willebrand factor staining, and immunoblotting for p-p42/44 (p-Erk1/2, p-MAPK) and p-AKT. Immunoblotting revealed expression of epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor-2 in all biliary tract cancer cell lines. EGFR was detectable in six of 19 (32%) extrahepatic human cholangiocarcinoma tissue samples, ErbB-2 in 16 of 19 (84%), and vascular endothelial growth factor receptor-2 in nine of 19 (47%). Neither epidermal growth factor receptor mutations nor amplifications or polysomy were found in the seven biliary tract cancer cell lines. Gefitinib, erlotinib and NVP-AEE788 caused a significant growth inhibition in vitro; however, there was a significant difference in efficacy (NVP-AEE788>erlotinib>gefitinib). After 14 days of in-vivo treatment, using the chimeric mouse model, tumors had a significantly reduced volume and mass after NVP-AEE788, but not after erlotinib treatment, as compared with placebo. Reduction of proliferation (signalling via the mitogen-activated protein kinase pathway), induction of apoptosis and inhibition of angiogenesis were the main mechanisms of drug action. No significant reduction of anti-apoptotic AKT phosphorylation, however, occurred, which may be a possible counter mechanism of the tumor. Epidermal growth factor receptor, ErbB-2, and vascular endothelial growth factor receptor-2 expression was detectable in biliary tract cancer, and receptor inhibition exerts marked effects on tumor growth in vitro and in vivo, which was strongest for the dual EGFR/ErbB-2 inhibitor NVP-AEE788. Therefore, further clinical evaluation of this new drug for the treatment of biliary tract cancer is recommended.
Similar articles
-
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).Int J Mol Med. 2007 Jul;20(1):3-10. Int J Mol Med. 2007. PMID: 17549382 Review.
-
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.Clin Cancer Res. 2006 Dec 15;12(24):7242-51. doi: 10.1158/1078-0432.CCR-06-0646. Clin Cancer Res. 2006. PMID: 17189395 Review.
-
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3425-34. doi: 10.1158/1078-0432.CCR-06-0793. Clin Cancer Res. 2006. PMID: 16740767
-
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.Cancer Res. 2004 Aug 1;64(15):5355-62. doi: 10.1158/0008-5472.CAN-04-0562. Cancer Res. 2004. PMID: 15289342
-
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681. Cancer Res. 2004. PMID: 15256466
Cited by
-
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview.Onco Targets Ther. 2021 Feb 25;14:1341-1366. doi: 10.2147/OTT.S297643. eCollection 2021. Onco Targets Ther. 2021. PMID: 33658799 Free PMC article. Review.
-
The Influence of Bisphenol A (BPA) on Neuregulin 1-Like Immunoreactive Nerve Fibers in the Wall of Porcine Uterus.Int J Mol Sci. 2018 Sep 28;19(10):2962. doi: 10.3390/ijms19102962. Int J Mol Sci. 2018. PMID: 30274171 Free PMC article.
-
Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy.Cell Mol Life Sci. 2017 Mar;74(6):1133-1151. doi: 10.1007/s00018-016-2401-0. Epub 2016 Nov 1. Cell Mol Life Sci. 2017. PMID: 27803950 Free PMC article.
-
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.ISRN Hepatol. 2014 Feb 16;2014:828074. doi: 10.1155/2014/828074. eCollection 2014. ISRN Hepatol. 2014. PMID: 27335842 Free PMC article. Review.
-
Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice.Oncotarget. 2015 Oct 13;6(31):31877-88. doi: 10.18632/oncotarget.5047. Oncotarget. 2015. PMID: 26397134 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous